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The subventricular zone (SVZ) is one of the main niches of neural stem cells in the adult
mammalian brain. Stem and precursor cells in this region are the source for neurogenesis
and oligodendrogesis, mainly in the olfactory bulb and corpus callosum, respectively.
The identification of the molecular components regulating the decision of these cells
to differentiate or maintain an undifferentiated state is important in order to understand
the modulation of neurogenic processes in physiological and pathological conditions.
PPARs are a group of transcription factors, activated by lipid ligands, with important
functions in cellular differentiation and proliferation in several tissues. In this work, we
demonstrate that mouse adult neural precursor cells (NPCs), in situ and in vitro, express
PPARβ/δ and PPARγ. Pharmacological activation of both PPARs isoforms induces
proliferation andmaintenance of the undifferentiated phenotype. Congruently, inhibition of
PPARβ/δ and PPARγ results in a decrease of proliferation and loss of the undifferentiated
phenotype. Interestingly, PPARγ regulates the level of EGFR in adult NPCs, concurrent
with it is function described in embryonic NPCs. Furthermore, we describe for the
first time that PPARβ/δ regulates SOX2 level in adult NPCs, probably through a direct
transcriptional regulation, as we identified two putative PPAR response elements in the
promoter region of Sox2. EGFR and SOX2 are key players in neural stem/precursor cells
self-renewal. Finally, rosiglitazone, a PPARγ ligand, increases PPARβ/δ level, suggesting
a possible cooperation between these two PPARs in the control of cell fate behavior.
Our work contributes to the understanding of the molecular mechanisms associated to
neural cell fate decision and places PPARβ/δ and PPARγ as interesting new targets of
modulation of mammalian brain homeostasis.
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Introduction
The subventricular zone of the lateral ventricles (SVZ) in the adult mammalian brain is one of
two major CNS neural stem cell niches. There, neural stem cells self-renew and differentiate into
neurons, oligodendrocytes and astrocytes (Gage et al., 1998; Doetsch et al., 1999; Rietze et al.,
2001; Rietze and Reynolds, 2006). Within the SVZ, Epidermal Growth Factor Receptor (EGFR)
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expressing stem cells (type B cells) give rise to rapidly divid-
ing transit-amplifying progeny (type C cells) which also express
EGFR, which in turn generate immature neuroblasts (type A
cells) (Doetsch et al., 2002). B and C cell populations are respon-
sible of making neurospheres in cultures (Doetsch et al., 2002;
Pastrana et al., 2009); and will be referred here as neural precur-
sor cells (NPCs). Regulation of NPCs cell fate involves a com-
plex and coordinated network of extrinsic and intrinsic signaling
pathways. Among the molecules that regulate NPCs pool prolif-
eration and maintenance, Sonic Hedgehog (Shh) and Epidermal
Growth Factor (EGF) have been addressed as important mito-
genic signals (Reynolds et al., 1992; Doetsch et al., 2002; Palma
et al., 2005; Reinchisi et al., 2013; Alvarez-Buylla and Ihrie, 2014).
In NPCs, EGFR signaling functions as a control system of cell
proliferation, not only by responding to its own ligands but also
by serving as a nodal element for a variety of other stimuli act-
ing through downstream effectors of EGFR signaling pathways
(Sibilia et al., 2007; Hu et al., 2010; Reinchisi et al., 2013). Cell-
intrinsic components committed in cell fate decisions involve
transcription factors, some of which play a role in self-renewal,
such as SOX2, BMI1 and TLX (Graham et al., 2003; Ferri et al.,
2004; Shi et al., 2004; Molofsky et al., 2005; Qu et al., 2010), while
others, like MASH1 (Casarosa et al., 1999; Cau et al., 2002), act
in neuronal differentiation. Although much progress has been
made in understanding NPCs function in the adult brain, the
detailed understanding of events regulating the delicate balance
between self-renewal capacity and stem cell fate is still far from
being clarified.
Peroxisome proliferator-activated receptors (PPARs), a sub-
group of the nuclear receptor superfamily, are ligand-activated
transcription factors (Issemann and Green, 1990, 1991). Three
isotypes of PPARs have been described in vertebrates, PPARα,
PPARβ/δ and PPARγ, which are highly conserved between
species (Issemann and Green, 1990, 1991; Dreyer et al., 1992;
Schmidt et al., 1992; Kliewer et al., 1994). PPARα is barely
expressed in the central nervous system of adult rodents (Brais-
sant et al., 1996). In contrast, a high expression level of PPARβ/δ
is observed in the developing neural tube and epidermis Braissant
and Wahli, 1998; Keller et al., 2000). In adult rodents, PPARβ/δ
is abundantly and ubiquitously expressed, although some tis-
sues such as brain, adipose tissue, and skin have higher mRNA
level (Kliewer et al., 1994; Braissant et al., 1996). PPARβ/δ has
important functions in proliferation, differentiation and cellular
survival in several cell types. In skin, induction of keratinocyte
proliferation by several stimuli, such as tetradecanoylphorbol
acetate, is associated with up-regulation of PPARβ/δ level in the
epidermis (Michalik et al., 2005). Moreover, PPARβ/δ-mutants
decrease the number of proliferative keratinocytes and display
increased apoptosis in early hair follicles (Di-Poi et al., 2005).
PPARβ/δ-null mice are also smaller than wild type littermates and
their brains present alterations in the myelinization of the corpus
callosum (Peters et al., 2000). Although PPARβ/δ is abundantly
expressed in the brain, a possible role of this factor modulating
NPCs behavior has not yet been studied.
Regarding PPARγ, expression pattern analysis of this fac-
tor shows a transient peak of expression in the central nervous
system between E13.5 and E15.5 (Braissant and Wahli, 1998;
Keller et al., 2000). Interestingly, NPCs cultures (neurosphere
assay) obtained at E13.5 from PPARγ+/− mice shows dimin-
ished cellular viability and EGFR level (Wada et al., 2006). On the
other hand, NPCs obtained from wild type embryos and treated
with rosiglitazone (PPARγ agonist) increase cellular viability and
EGFR level, suggesting a role of this isotype in NPCs self-renewal
(Wada et al., 2006). In vivo treatments with PPARγ agonists,
namely pioglitazone and rosiglitazone, also increase both cellu-
lar proliferation and differentiation in the SVZ (Morales-Garcia
et al., 2011). Recently, Ghoochani et al. evaluated PPARγ level
during induced neuronal differentiation of mouse embryonic
stem cells (mESC) in vitro. They observed an increase in PPARγ
level in NPCs, which dropped inmature neurons. PPARγ antago-
nist decreased the expression of terminal differentiation markers
suggesting a role of this transcription factor in the maintenance
of the neural stem/precursor phenotype (Ghoochani et al., 2012).
The aim of the present study was to evaluate the potential role
of PPARβ/δ and PPARγ in mouse adult NPCs. Our experiments
establish the presence of both receptors in precursor cells in situ
and in vitro.We also show that PPARγ regulates proliferation and
maintenance of the precursor phenotype and modulates EGFR
level in adult NPCs, a result that complements the function of
this factor in embryonic mice NPCs (Wada et al., 2006). Finally,
we describe for the first time that PPARβ/δ maintains the undif-
ferentiated phenotype of adult NPCs and regulates SOX2 level, a
key component of self-renewal. Our results identify PPARγ and
PPARβ/δ as regulators of adult neural precursor cell behavior.
Materials and Methods
Reagents and Antibodies
GW0742 and GSK0660 were purchased from Sigma-Aldrich
(St. Lois, MO, USA). Rosiglitazone, GW9662 and Bisphenol A
diglycidyl ether (BADGE) are from Cayman Chemical Com-
pany (Ann Arbor, MI, USA). 5-bromo-2′deoxyuridine is from
Sigma-Aldrich (St. Lois, MO, USA). Anti-PPARβ/δ and anti-Myc
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-PPARγ, anti-GFAP (Glial fibrillary acidic protein),
anti-DCX (Doublecortin) and anti-SOX2 are from Cell Signaling
Technology (Beverly, MA, USA). Anti-Nestin and anti-EGFR are
from Millipore (Billerica, MA, USA), anti-Galactocerebroside C
(GalC) was purchased from Sigma-Aldrich (St. Lois, MO, USA),
anti-5-bromo-2′deoxyuridine is from Abcam (Cambridge, MA,
USA) and anti-βIII-Tubulin is from Promega (Madison, WI,
USA). Restriction enzymes are all from New England Biolabs
(Ipswich, MA, USA). GoTaq Flexi DNA Polymerase and RT-PCR
reagents were purchased from Promega (Madison, WI, USA)
and Invitrogen (Grand Island, NY, USA). siRNA-PPARβ/δ was
purchased from Santa Cruz Biotechonology, siRNA-control and
siGlo-Green Transfection Indicator were obtained from Thermo
Fisher Scientific, Dharmacon Inc (Lafayette, CO, USA).
Generation of Reporter and Expression Vectors
Three direct tandems of the peroxisome proliferator response
element (PPRE) sequence from the acyl-CoA Oxidase gene
were obtained from an original vector, donated by Dr. R. M.
Evans (Howard Hughes Medical Institute, The Salk Institute
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for Biological Studies, La Jolla, CA) (Forman et al., 1995).
This sequence was digested with BamHI and HindIII restric-
tion enzymes and was inserted into the commercial vector tkLuc
(ATCC, Manassas, VA, USA), specifically, in the 5′ region of the
thymidine kinase promoter. This new vector was denominated
tkPPRELuc. A luciferase gene was deleted from both vectors
(tkLuc and tkPPRELuc) by enzymatic digestion with XhoI and
SmaI, and replaced with full-length E. coli βGalactosidase gene,
which was obtained from commercial vector pCMVβ (Clontech,
Mountain View, CA, USA), by digestion with XhoI and SalI.
These vectors were named tkβGal and tkPPREβGal, respectively.
For Myc-PPARβ/δ vector construction, mouse cDNA of
PPARβ/δ was obtained from vector pCMX-PPARβ/δ (donated
by Dr. R. M. Evans), by digestion with BamHI and HindIII
restriction enzymes, and inserted in pCDNA3-NLS-Myc vector
(donated by Dr. Hugo Olguín, Cellular and Molecular Biology
Department, P. Catholic University of Chile; Olguin et al., 2007).
These restriction sites delete the NLS sequence. For expression
and functional analysis of theMyc-PPARβ/δ vector, HEK293 cells
were transiently transfected with Lipofectamine-2000 Reagent
(Invitrogen, Grand Island, NY, USA). Expression was analyzed
by western blot and cellular localization by immunofluorescence.
Activity was evaluated for luciferase reporter assay. We did not
observe statistical differences in the activity and localization
between both vectors (Supplementary Figure 1). All constructs
were verified by DNA sequencing.
Isolation and Culture of Adult Mice NPCs
This study was carried out in strict accordance with the recom-
mendations of the Biosecurity Guide of CONICYT (Comisión
Nacional de Investigación Científica y Tecnológica). The Bioeth-
ical Committees of Pontifical Catholic University of Chile and
University of Chile approved all protocols. We used three-
month-old C57bl/6 mice. NPCs culture was prepared accord-
ing to published protocols (Rietze and Reynolds, 2006; Brewer
and Torricelli, 2007). Briefly, the lateral walls of the ventri-
cles, i.e., striatal SVZ, of adult mice brains were dissected, incu-
bated with papain and dissociated with a fire-polished glass
pipette in the presence of DNaseI and Ovomucoid (Worthing-
ton Biochemical Corporation, Lakewood, NJ). NPCs were cul-
tured as neurospheres in neurobasal medium supplemented with
B27minus vitamin A, 200mM L-Glutamine (Invitrogen), peni-
cillin/streptomycin (Invitrogen) and 10 ng/ml EGF (Invitrogen).
After 7 days in culture, primary neurospheres were dissociated,
centrifuged at 110× g, re-suspended and seeded at a density
of 10.000 cells/cm2 and cultured in the same conditions, in
order to generate secondary neurospheres. For all assays we used
NPCs seeded as adherent cells. Secondary neurospheres were
dissociated into single cells using trypsin-EDTA (Invitrogen),
plated onto poly-l-ornithine/laminin (Sigma-Aldrich and Invit-
rogen, respectively), and cultured as monolayers in a complete
medium (neurobasal medium supplemented with B27minus
vitamin A, penicillin/streptomycin, 200mM L-Glutamine and
10 ng/ml EGF). For differentiation assays, cells were cultivated
in neurobasal medium supplemented with B27minus vitamin
A, 200mM L-Glutamine, penicillin/streptomycin and 0.1% fetal
bovine serum, without EGF, in absence or presence of drugs.
Western Blot
Cells were washed with phosphate buffered saline (PBS), lysed
and centrifuged at 14.000 xg for 10min at 4◦C. For EGFR
detection, lysis buffer was 50mM Tris-HCl pH 7.5, 150mM
NaCl, 1mM CaCl2, 1mM MgCl2 and 0,5% Nonidet P-40 (Gar-
cion et al., 2004). For detection of all other proteins, we used
RIPA buffer (20mM Tris-HCl, 150mM NaCl, 1mM EDTA,
1mM EGTA, 1% Nonidet P-40 and 1% sodium deoxycholate).
Both buffers were supplemented with protease and phosphatase
inhibitors mixture (Roche Applied Science, Mannheim, Ger-
many). Proteins were resolved by SDS-PAGE and transferred
into PVDF membranes. Blots were subsequently incubated
with antibodies as follows: Anti-PPARβ/δ (1:1000), anti-PPARγ
(1:1000), anti-EGFR (1:1000), anti-Nestin (1:5000), anti SOX2
(1:2000). For detection, horseradish peroxidase-conjugated sec-
ondary antibodies (Santa Cruz Biotechnology) were used fol-
lowed by enhanced chemiluminescence detection (Perkin Elmer
Inc., Waltham, MA). Optical density was quantified with ImageJ
software.
Reverse Transcriptase Polymerase Chain
Reaction (RT-PCR)
Total RNA was isolated from NPCs using Trizol Reagent
(Invitrogen. Grand Island, NY, USA) and treated with DNase
I (Promega. Madison, WI, USA). 2µg of RNA was reverse
transcribed with SuperScript II Reverse Transcriptase (Invitro-
gen) and Oligo(dT), according to the manufacturer’s instruc-
tions. The following primers were used for PCR reactions:
forward-PPARβ/δ 5′-GCA GCC TCT TCC TCA ATG AC-3′
and reverse-PPARβ/δ 5′-CCG TCT TCT TTA GCC ACT GC-3′,
forward-PPARγ 5′-CTG GCC TCC CTG ATG AAT AA-3′and
reverse-PPARγ 5′-ACG TGC TCT GTG ACG ATC TG-3′,
Forward-GADPH 5′-TGA CCA CAG TCC ATG CCA TC-3 and
reverse-GADPH 5′-GACGGACACATTGGGGGTAG-3′. The
following PCR conditions were used: 94◦C for 5min, followed
by 35 cycles of 94◦C (30 s), 55◦C or 60◦C (30 s) and 72◦C (30 s).
GoTaq Flexi DNA Polymerase and 2mM MgCl2 were used in
all reactions (Promega. Madison, WI, USA). Fragments were
analyzed with agarose gel electrophoresis (2%) and SYBR-Safe
staining (Invitrogen).
BrdU Incorporation Assays
For in vitro BrdU-incorporation assays, NPCs were incu-
bated with 10µM BrdU for 6 h previous to fixation in 4%
paraformaldehyde. Samples were incubated 10min in HCl 2 M,
thrice in Sodium Borate Buffer 0,1M pH 8,5 (10min each time)
and permeabilized/blocked in PBS 0.1% Triton-×100 and 5%
normal donkey serum for 30min. Anti-BrdU antibody (1:500,
Abcam. Cambridge, MA, USA) was incubated for 2 h at 37◦C.
Cy2-conjugated anti-rat IgG was used as a secondary antibody
(1:500, Abcam) and incubated for 1 h at room temperature.
BrdU-positive cells were evaluated using an Epifluorescent Axio-
plan Microscope and AxioCamMRm (Zeiss). BrdU positive cells
were counted in 15 randomly selected fields from three differ-
ent coverslips, for each experiment. We used DAPI for total cells
count. At least three independent experiments were carried out
for each assay.
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For in vivo BrdU-incorporation assays, mice were intraperi-
toneally injected with 100mg BrdU/Kg of animal body weight
for 5 days. At day 5, mice were anesthetized and perfused
intracardially with PBS, followed by cold 4% paraformalde-
hyde solution. Brains were collected and post-fixed overnight
in 4% paraformaldehyde, followed by 24 h immersion in a 20%
sucrose solution. Brains were included in OCT. Coronal sec-
tions (30µm) from SVZ were processed for immunofluores-
cence. Briefly, slices were incubated 20min in 0.13MNaBH4 and
washed with PBS, then incubated 10min in HCl 2 M, 10min in
Sodium Borate Buffer 0,1M pH 8,5, thrice in TBS and perme-
abilized/blocked in TBS 0.1% Triton-×100 and 5% normal don-
key serum for 30min. Primary antibodies, anti-BrdU (1:1000)
and anti-PPARβ/δ (1:100), were incubated for 48 h at 4◦C. Alexa
Fluor secondary antibodies (Invitrogen) or Cy2 secondary anti-
body (Abcam) were incubated for 1 h at room temperature. This
protocol was modified from Valero et al. (2005) and Wojtowicz
and Kee (2006).
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde, permeabilized/blocked
in PBS-0.1%Triton-X100/5% normal donkey serum for 1 h and
incubated in primary antibodies at 4◦C overnight. The follow-
ing primary antibodies were used: anti-PPARβ/δ (1:100), anti-β-
Galactosidase (1:1000), anti-Nestin (1:1000), anti-DCX (1/500),
anti-SOX2 (1:200) and anti-Myc (1:500). Alexa-Fluor secondary
antibodies (1:1000) were incubated 1 h at room temperature.
DAPI (Invitrogen) was used for nuclei detection. Samples were
examined in an Epifluorescent Axioplan Microscope and Axio-
Cam MRm (Zeiss), or in a Fluoview 1000 Confocal Microscope
(Olympus). ImageJ Programwas used to analyze and quantify the
images.
Nucleofection of Mouse Adult NPCs
Nucleofection of adult NPCs was performed, using the mouse
NSC NucleofectorTM Kit and optimized protocols provided by
the manufacturer (Amaxa Biosystem, Cologne, Germany). Live
and dead cells were counted by trypan blue staining in Neubauer
hemocytometer after nucleofection and cells were plated onto
poly-l-ornithine/laminin coated coverslips in a medium supple-
mented with growth factors. 24 h after nucleofection, cells were
treated with PPAR ligands, for time and concentrations as indi-
cated in the results section. For PPAR reporter assay, images
were acquired with an Epifluorescent Axioplan Microscope and
AxioCamMRm (Zeiss). Cells were delimited and βGalactosidase
fluorescence was quantified using ImageJ.
Transfection of siRNA
Cells were seeded onto poly-l-ornithine/laminin coated coverslip
in a complete medium supplemented with EGF. Cells were
co-transfected with siGlo-Green/siRNA-Control or siGlo-
Green/siRNA-PPARβ/δ using DharmaFECT 3 transfection
reagent (Dharmacon), according to the manufacturer’s instruc-
tions. Transfected cells were maintained in complete medium
with EGF for 48 h, the medium was replaced every day. Silenc-
ing of PPARβ/δ was evaluated by western blot and followed
by anti-SOX2 immunofluorescence. Images were taken with
an Epifluorescent Axioplan Microscope and AxioCam MRm
(Zeiss). SOX2 fluorescence was quantified in siGloGreen positive
cells. As SOX2 is a nuclear factor, nucleus was delimited in DAPI
positive area and fluorescence of SOX2 was quantified in this
region using ImageJ program.
Statistical Analysis
Mann Whitney Test and One-Way ANOVA-Bonferroni were
used to analyze the statistical differences of means. p < 0.05 (95%
confidence intervals) was considered significant. Prism Program
was used for all analysis. Values are expressed asmean± standard
error of the mean (SEM).
Results
PPARβ/δ and PPARγ are Present in Mouse Adult
SVZ NPCs and Activities of these Receptors are
Inducible by Exogenous Ligands
In order to evaluate if PPARβ/δ and PPARγ are expressed in
proliferating NPCs in the SVZ, adult mice were injected for
5 days intraperitoneally with BrdU followed by immunostain-
ing on coronal brain sections. We observed that both PPARβ/δ
and PPARγ are expressed in BrdU positive cells in the SVZ of
adult mice, as detected by co-labeling with BrdU immunostaining
(Figure 1A). Both PPARs have a nuclear expression. As previ-
ously described (Braissant et al., 1996), PPARβ/δ expression is
also observed in striatum and cortex. In order to establish a pos-
sible role of PPARs in these progenitors, we prepared primary
cultures of NPCs from the SVZ of adult mice. PPARβ/δ and
PPARγ are expressed in NPCs in vitro (Figures 1B,C) displaying
mainly a nuclear localization, as revealed by immunofluorescence
(Figure 1D).
Next, we sought to find out if PPARs are transcriptionally
active in vitro and if their activity is inducible by exogenous
ligands in these cells. In order to detect PPAR transcriptional
activity, we generated βGalactosidase reporter vectors, called
tkPPREβGal and tkβGal (see Material and Methods Section),
which allowed us to detect PPAR activity in situ by immunoflu-
orescence. This method was applied due to low plasmid trans-
fection efficiency of NPCs (15.53 ± 5.43% for Nucleofection and
4.40 ± 1.71 for Lipofectamine-2000 Reagent; Mean ± SD). To
be able to identify cells carrying βGalactosidase vectors and sub-
sequently quantify fluorescence intensity of βGalactosidase on
these cells, we performed co-transfection with an EGFP vector.
Co-transfection efficiency in NPCs in our system was 56.85 ±
14.49% (mean ± SD), as evaluated by co-nucleofection of EGFP
and dsRed-N1 vectors. Transfected cells were treated for 24 h
with a PPARβ/δ agonist (GW0742) or vehicle (DMSO). In con-
trol condition, we observed that NPCs transfected with tkβGal
presented a 3.8-fold lower intensity of fluorescence vs. cells
transfected with tkPPREβGal. When NPCs transfected with the
tkPPREβGal vector were treated with GW0742, we detected a 5-
fold increase in the fluorescence intensity with respect to cells
treated with DMSO (Figures 1E,F). In line with this observa-
tion, Rosiglitazone (PPARγ agonist) increased the fluorescence
intensity 7 times with respect to the control.
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FIGURE 1 | PPARβ/δ and PPARγ are expressed in adult NPCs and their
transcriptional activity is inducible by exogenous ligands. (A) Adult mice
were injected with 100mg BrdU/Kg animal body weight for labeling of
(Continued)
FIGURE 1 | Continued
proliferative cells. Brain coronal sections of 30µm were immunostained with
anti-PPARβ/δ or anti- PPARγ (red) and anti-BrdU (green) antibodies. Samples
were analyzed by confocal microscopy. (B) RT-PCR for PPARβ/δ and PPARγ:
RNA was extracted from SVZ NPCs. Neocortical and adipose tissues from
adult mice were used as positive controls (C+), respectively. (C) Western blots
anti-PPARβ/δ and PPARγ. (D) Immunofluorescence anti-PPARβ/δ and PPARγ.
(E,F) In situ transcriptional activity assay: Adult NPCs were transiently
co-transfected with pEGFP-C1 reporter vector and tkPPREβGal (PPAR activity
transcriptional reporter vector) or tkβGal (empty vector). Cells were treated with
GW0742 1µM, Rosiglitazone 1µM (RGZ) or DMSO (vehicle) for 24 h.
Immunofluorescence anti-βGalactosidase (βGal) was performed. Fluorescence
intensity was quantified by ImageJ program. Graphic in (E) represent the mean
fluorescence intensity ± s.e.m (∗p < 0.05). AU, Arbitrary Units.
These results reveal endogenous transcriptional activity of
PPARs in adult SVZ-NPCs, and also that their activities can be
induced by exogenous ligands.
PPARβ/δ and PPARγ Agonists Induce
Proliferation of NPCs
Having established that PPARβ/δ is expressed in NPCs and
that this activity is inducible by exogenous ligand in vitro, we
next evaluated if PPARβ/δ plays a role in NPCs proliferation
by performing a BrdU incorporation assay. NPCs were seeded
as a monolayer in presence of 10 ng/ml of EGF and treated
with PPARβ/δ ligands. A BrdU pulse was performed 6 h previ-
ous to the experiment end-point. Cell proliferation showed an
increase of almost 30% in cultures treated with PPARβ/δ ago-
nist (GW0742) for 24 h and this effect was reverted by incu-
bation with a PPARβ/δ antagonist (GSK0660), suggesting that
this increase is indeed PPARβ/δ-dependent (Figures 2A,B). We
should note that we did not observe any effect of antagonist
treatment in basal conditions in a 24 h treatment. Neverthe-
less, when cells were treated with the same antagonist for a
longer time period (48 h), we did observe a small but statisti-
cally significant decrease in the percentage of BrdU positive cells
(32.12 ± 0.66 v/s 27.28 ± 1.04; p = 0.003) (Figures 2C,E). We
did not see differences in the percentage of activated caspase-3,
as evaluated by immunofluorescence (Figures 2D,F), indicating
that apoptosis does not account for this decrease. Rosiglitazone,
a PPARγ agonist, also induced an increase of proliferation in
NPCs treated for 24 h, an effect that is reverted by a PPARγ
antagonist (BADGE). Unlike the PPARβ/δ antagonist, BADGE
is able to decrease basal level of BrdU incorporation at 24 h
(Figures 2G,H).
PPARβ/δ Antagonist Drives Differentiation of
NPCs Even in Presence of EGF
In addition to regulating proliferation, PPARβ/δ could also act by
maintaining the NPCs pool. In order to evaluate this hypothe-
sis, NPCs, seeded as single cells over poly-L-ornithine/laminin,
were treated with the PPARβ/δ antagonist for 48 h, in presence of
10 ng/ml EGF. A precursor phenotype was evaluated for Nestin,
GFAP and SOX2 expression. In control samples, over 95% of the
cells were positive for SOX2 and Nestin expression. Nestin posi-
tive cells showed a relative homogenous morphology, with two or
three thin processes of different lengths (Figure 3A). In contrast,
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FIGURE 2 | PPARβ/δ and PPARγ ligands regulate cell
proliferation. (A) NPCs cultures were treated with a vehicle
(DMSO), 1µM GW0742 (GW; PPARβ/δ agonist), 5µM GSK0660
(GSK; PPARβ/δ antagonist) or both, for 24 h, in the presence of
10 ng/ml EGF. BrdU was added to the cultures followed by
anti-BrdU immunodetection. Graphic in (B) represents the mean
percentage of BrdU positive cells ± s.e.m. of three independent
experiments N = 3; ∗∗p < 0.01. (C) Cells were treated with 5µM
GSK0660 or a vehicle (DMSO) for 48 h in the presence of 10 ng/ml
EGF. BrdU was added to the cultures 6 h prior to fixation.
Immunostaining with anti-BrdU was performed. The Graph in (E)
represents the mean percentage of BrdU positive cells ± s.e.m.
(*p = 0.012, Mann Whitney Test). (D) Cells were treated with 5µM
GSK0660 or a vehicle (DMSO) for 48 h in the presence of 10 ng/ml
EGF. Immunofluorescence anti-Activated Caspase3 (Cas3-Ac) was
performed to identify apoptotic cells. The Graph in (F) represents
the mean percentage of Caspase3-Ac positive cells ± s.e.m. of
three independent experiments. No statistical differences were
observed (N = 3; p = 0.4338). (G) Adult NPCs were treated with a
vehicle (DMSO), 1µM Rosiglitazone (RGZ; PPARγ agonist), 50µM of
BADGE (PPARγ antagonist) or both, for 24 h, in the presence of
10 ng/ml EGF. Immunodetection with anti-BrdU is shown. The Graph
in (H) represents the mean percentage of BrdU positive cells ±
s.e.m. of three independent experiments N = 3; ∗∗p < 0.01.
a significant decrease in Nestin positive cells in cultures treated
with the drug was observed (95.10 ± 0.55% vs. 69.06 ± 2.74%;
p < 0.0001) (Figures 3A,B). In addition, a decrease in fluores-
cence intensity was also observed as shown in Figure 3A. GFAP
during late cortical embryogenesis and in adult SVZ is consid-
ered a marker of many terminally differentiated astrocytes, but
has also been reported as a NSC/Radial glia marker. Therefore, in
order to check if GFAP labeling is related to NPCs or to mature
astrocyte, we co-labeled the cells with the stem cell marker SOX2.
In control conditions, 89.41 ± 5.66% of the GFAP positive cells
are SOX2+/GFAP+ vs. 10.60 ± 5.66% SOX−/GFAP+; cultures
treated with the antagonist (5µM GSK0660) changed these per-
centages to 46.90± 7.34% vs. 53.10± 7.34%, for SOX2+/GFAP+
and SOX2−/GFAP+, respectively (Figures 3C,D). In agreement
with these results, we also observed a clear change in the mor-
phology of these cells. In the presence of the PPARβ/δ antagonist,
GFAP positive cells presented a greater number of processes and
the projections were thicker, a suggestive morphology of mature
astrocytes (Figure 3C). In addition, treatment with this inhibitor
resulted in an increase in the percentage of neurons in the cul-
ture. It should be noted that a spontaneous but minimal neu-
ronal differentiation is observed in presence of growth factors
when monolayer cultures are maintained for 3 days or more in
normal conditions (medium supplemented with 10 ng/ml EGF),
as evidenced by a 0.50 ± 0.14% of DCX positive cells. But
in cultures treated with the PPARβ/δ antagonist, the percent-
age increased to 1.12 ± 0.14% (p < 0.0001) and some cells
even displayed morphologies characteristic of mature neurons
in contrast with DCX positive cell morphologies observed in
the controls (Figures 3E,F). Finally, regarding oligodendrocytes,
neither in the controls nor after treatments, we were able to
observe changes, as evaluated by an immunofluorescence anti-
GalC (data not shown). From these results, it clearly emerges
that PPARβ/δ participates in the maintenance of the precursor
phenotype.
PPARβ/δ Regulates SOX2 Level in NPCs In Vitro
SOX2 is an important regulator of NPCs self-renewal and since
we observed a decrease in its expression level after treatment with
the PPARβ/δ antagonist by immunostaining (Figures 3C,D), we
were interested in evaluating if this receptor regulates SOX2
directly. Indeed, PPARβ/δ antagonist decreased SOX2 expres-
sion below the basal level, acting in a dose dependent manner,
whereas the agonist increased SOX2 level (Figure 4A). In order
to characterize the PPARβ/δ overexpression effect, we took two
issues into consideration: 1) adult NPCs present low transfec-
tion efficiency, complicating the analysis by western blot and 2)
PPARβ/δ is already expressed in basal conditions in adult NPCs.
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FIGURE 3 | PPARβ/δ antagonist diminished precursor phenotype.
Adult NPCs were treated with 5µM GSK0660 or the vehicle
(DMSO) for 48 h in the presence of 10 ng/ml EGF. Different markers
were evaluated by immunofluorescence. Quantification of percentage
in different conditions was performed and shown in the graphs. (A)
Immunofluorescence anti-Nestin. (C) Immunofluorescence
anti-GFAP/SOX2. In GSK0660 treated cells we detected a change
in the percentage of GFAP+/SOX+ and GFAP+/SOX2− cells, as
observed in the graph. Control shows a representative image of
GFAP+/SOX2+ cells, the predominant population. GSK0660 shows a
representative image of GFAP+/SOX2− cells, whose population
increased in this condition. In both conditions, light gray bars
represent GFAP+/SOX2+ cells and dark gray bars represent
GFAP+/SOX2− cells. Percentages expressed are in respect to the
total GFAP+ cells. (E) Immunofluorescence anti-DCX. Graph in
(B,D,F), represent the mean percentage of positive cells ± s.e.m.
of three independent experiments. Bars correspond to 20µm. Mann
Whitney Test was applied in (B,F) and One-way ANOVA-Bonferroni
Test was applied in (D). (∗p < 0.05, ∗∗p = 0.01 to 0.001,
∗∗∗p < 0.001).
To overcome these difficulties, we generated a PPARβ/δ expres-
sion vector with an additional tag (Myc-PPARβ/δ), allowing us
thereby to identify individual transfected cells that were over-
expressing PPARβ/δ. The expression and functionality of the
Myc-PPARβ/δ vector were evaluated first in a Hek293 cell line.
We did not observe any change in cell behavior and activity
of Myc-PPARβ/δ in comparison to PPARβ/δ without the tag
(Supplementary Figure 1).
NPCs were transfected with Myc-PPARβ/δ and ectopic
expression of PPARβ/δ in the cells was evaluated by anti-
Myc immunofluorescence. Transfected cells were treated with
PPARβ/δ agonist (GW0742) or vehicle (DMSO) for 24 h, fol-
lowed by an anti-SOX2/anti-Myc co-immunofluorescence. The
fluorescence intensity of SOX2 was evaluated in both Myc-
PPARβ/δ positive and negative cells, in presence or absence
of the agonist. In control conditions (DMSO) we were able
to observe a 1.78-fold increase in the SOX2 fluorescence
intensity in Myc-PPARβ/δ positive cells with respect to Myc-
PPARβ/δ negative cells. When cells were cultured in the pres-
ence of PPARβ/δ agonist (GW0742), the fluorescence intensity
increased in both conditions, Myc-PPARβ/δ negative and posi-
tive cells, but the increment in Myc-PPARβ/δ positive cells were
much greater (1.76-fold vs. 2.44-fold, in Myc-PPARβ/δ nega-
tive and positive cells, respectively, both treated with GW0742
compared to Myc-PPARβ/δ negative cells treated with the
vehicle). We did not observe statistical differences between
Myc-PPARβ/δ positive cells treated with GW0742 or vehicle
(Figure 4B).
PPARβ/δ is Necessary for SOX2 Expression in
Mouse Adult NPCs from the SVZ
In order to establish if PPARβ/δ is necessary for SOX2 main-
tenance, we subsequently did a knock down of this factor
in NPCs by using siRNA, co-transfecting either siGlo-Green
with siRNA-PPARβ/δ or the siRNA-control. Transfection effi-
ciency was higher than 80% (Percentage of siGLO-Green pos-
itive cells). Interestingly, we observed an average decrease of
0.6-fold in the fluorescence intensity of SOX2 in cells trans-
fected with siRNA-PPARβ/δ with respect to the control (p <
0.0001; Figures 4C,D). Next, NPCs were transfected with siRNA-
PPARβ/δ or siRNA-control and treated with 1µM GW0742
for 24 h in the presence of 10 ng/ml of EGF, followed by anti-
PPARβ/δ and anti-SOX2 Western blots. An expected increase
of SOX2 level was observed in control cells treated with the
agonist, as already observed (Figures 4A,E). Moreover, PPARβ/δ
knockdown decreased SOX2 level while PPARβ/δ agonist in
this condition was not able to increase the level of SOX2
(Figure 4E).
Thus, our results show that PPARβ/δ contributes toward
the maintenance of the precursor phenotype and regulates
SOX2 level in adult NPCs. Since PPARβ/δ is a transcrip-
tion factor that regulates the expression of its target genes
by recognizing specific sequence denominated PPRE (PPAR
response element) in the regulatory region, we analyzed the
mouse Sox2 gene (Gene ID 20674) for the presence of possi-
ble response elements in the promoter region. Note that the
Mat Inspector Program revealed two putative PPREs in the
positions −203 to −225 (GTCTTGGTGCTGTTTACCCACTT)
and −244 to −266 (CCGTTTTCAGCAACAGGTCACGG), in
respect of the transcription site, suggesting a direct transcrip-
tional regulation of Sox2 by PPARβ/δ. Further in vitro studies will
be required to confirm this in silico result.
PPARγ and PPARβ/δ Regulate EGFR level in NPCs
As already shown, PPARβ/δ regulates SOX2 level in NPCs
in vitro. SOX2 is an important transcription factor necessary in
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FIGURE 4 | PPARβ/δ regulate SOX2 level in adult NPCs. (A) NPCs were
treated for 24 h at different concentrations of GW0742 or GSK0660 as
indicated, in the presence of 10 ng/ml EGF. Total proteins were analyzed by
western blot for anti-SOX2. Graph represents the mean ± s.e.m. of three
independent experiments. One-Way ANOVA-Bonferroni Test was applied.
(B) Myc-PPARβ/δ expression vector was transiently transfected. Cells were
treated with 1µM GW0742 (agonist) or a vehicle (DMSO) for
24 h.Immunofluorescence anti-SOX2/anti-Myc was realized.
(Continued)
FIGURE 4 | Continued
SOX2 fluorescence intensity was quantified in both Myc positive and negative
cells. Graph represents the mean ± s.e.m. of three independent
experiments.One-Way ANOVA-Bonferroni Test was applied. (C) Adult NPCs
were transiently co-transfected with siGLO-Green and siRNA-PPARβ/δ or
siRNA-control, in the presence of 10 ng/ml of EGF. SOX2 fluorescence
intensity was quantified in siGLO-Green positive cells. Representative images
of cells observed and quantified are shown. White arrows shows siGLO-Green
positive cell. Red arrow shows a siGLO-Green negative cell. Graph in (D)
represents the mean ± s.e.m. (E) NPCs were transfected with siRNA-PPARβ/δ
or siRNA-control, under the same condition as in (C). Cells transfected were
treated with 1µM GW0742 (GW) for 24 h in the presence of 10 ng/ml of EGF.
Western blots anti-PPARβ/δ and anti-SOX2, Total protein extract from HEK293
cells transiently transfected with pCMX- PPARβ/δ was used as a positive
control (C+). (∗p < 0.05, ∗∗p = 0.01–0.001, ∗∗∗p < 0.001, Mann Whitney
Test). DM, DMSO; GW, GW0742; AU, Arbitrary Units.
the maintenance of undifferentiated phenotypes of these cells.
Interestingly, it generates a positive feedback loop with EGFR,
also involved in self-renewal of NPCs (Hu et al., 2010). Addi-
tionally, Wada et al. reported recently that PPARγ regulates
EGFR level in embryonic mouse NPCs (E13.5–E14.5), increasing
thereby their cellular viability. We therefore decided to evaluate
if PPARγ has the same effect on adult NPCs as on embryonic
ones and, in addition, if PPARβ/δ is also able to regulate EGFR
level.
We observed that the PPARγ agonist (Rosiglitazone)
increased EGFR level at 12 h and this effect lasted up to
24 h (Figures 5A,B). This effect is reverted by the antagonist
(BADGE), suggesting PPARγ dependence. Moreover, an increase
in the EGFR level at short times (15–30min) in respect to
time zero was also observed in both control and treated cells,
consistent with data reported by Hu et al. and probably due to
the addition of EGF to the culture (Hu et al., 2010). Nevertheless,
we did not observe statistically significant differences between
treatments at these short times (data not shown). Finally,
when PPARγ was overexpressed in adult NPCs, concomitant
to the higher proliferation rate of NPCs cultures, we found
increased EGFR level, even in basal conditions (Figure 5C).
Remarkably, 24 h treatment with the agonist also increased
PPARβ/δ protein level in a concentration-dependent manner
indicating a possible collaborative function between PPARs
(Figure 5D).
With regard to the PPARβ/δ function over EGFR level, NPCs
were treated for 24 h with PPARβ/δ agonist (GW0742) and EGFR
protein was evaluated by western blot. We did not observe any
difference between treatment and control (Figure 5E). However,
when cells were treated with the antagonist (GSK0660) for 48 h
at a concentration of 10µM, protein level of EGFR was clearly
diminished (Figure 5F).
We conclude that PPARγ regulates EGFR level in adult
NPCs. Additionally, that the inhibition of PPARβ/δ alone is
able to modulate EGFR level, with a different kinetic action
regarding PPARγ, suggesting an indirect effect of PPARβ/δ over
EGFR. Finally, PPARγ regulates PPARβ/δ level suggesting a
cooperative effect in the maintenance of NPCs undifferentiated
phenotype.
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FIGURE 5 | PPARγ regulate EGFR level in adult NPCs. (A) NPCs were
treated with 1µM rosiglitazone (RGZ) or a vehicle (DMSO), for the times
indicated. Proteins were analyzed by western blot anti-EGFR. αTubulin was
used as a loading control. In (B) graph represents the mean ± s.e.m. of three
independent experiments (One-way ANOVA-Bonferroni test; ∗ p < 0.05). (C)
NPCs were transfected with PPARγ1 expression vector (pPPARγ) or empty
vector (pCMX) and treated with 1µM Rosiglitazone (RGZ) or a vehicle (DMSO)
for 24 h. Total proteins were analyzed by western blot for anti-EGFR. Western
blot with anti-PPARγ is also shown. Only PPARγ overexpression increases
EGFR level up to 3-fold. (D) Adult NPCs were treated for 24 h with RGZ at the
concentrations indicated in the figure. PPARβ/δ level were analyzed by western
blot. Adult NPCs were treated with GW0742 (E) and GSK0660 (F) at different
concentrations. Level of EGFR was evaluated by western blot.
Discussion
In this study we reveal a new role of PPARs acting in
maintenance of adult NPCs undifferentiated phenotype in vitro.
We demonstrate the presence of PPARβ/δ and PPARγ in pro-
liferative cells in the SVZ in situ and describe their mainly
nuclear expression pattern in NPCs cultures. PPARs appear to
have endogenous activity in these cells and their activity can be
induced by exogenous ligands, as shown by pharmacological acti-
vation, thereby allowing a detailed functional analysis of PPARs
in NPCs. Our results, therefore, imply an endogenous activity of
PPARs regulating NPCs behavior.
PPARβ/δ is a transcription factor expressed, with high level in
selected tissues such as skin, fat and brain. Over 90% of PPARβ/δ-
null mice are not viable and die at early embryonic stages, mainly
due to placental disorders (Barak et al., 2002). The surviving
mutant mice have disorders in myelination of the central ner-
vous system and decreased adipose mass. In adipose tissue and
skin, PPARβ/δ has a role in apoptosis, proliferation and differ-
entiation (Peters et al., 2000; Di-Poi et al., 2005). Here we show
that PPARβ/δ contributes to maintain undifferentiated pheno-
type and regulates proliferation of adult NPCs in vitro. These
two important functions are involved in self-renewal of NPCs, an
essential property in vivo to maintain the NPCs pool in specific
regions of the adult brain.
One of the most important factors involved in NPCs self-
renewal is SOX2. Adult Sox2-KO mice present reduced prolifer-
ation and neurogenesis in SVZ and Hippocampus (Ferri et al.,
2004). Interestingly, we show that PPARβ/δ is a regulator of
SOX2 levels. Moreover, PPARβ/δ is necessary for SOX2 expres-
sion. Consistent with this notion, we found two putative PPRE
elements in the promoter region of this factor, suggesting a direct
role in its transcriptional control. SOX2 is not only necessary for
maintenance of the embryonic and adult neural stem/precursor
phenotype, it also has been demonstrated that this factor is essen-
tial for inner cell mass embryonic stem cells, as its ablation causes
early embryonic lethality (Avilion et al., 2003). Moreover, SOX2
is one of four-transcription factors necessary for induction of
fibroblast to pluripotent cells (Takahashi et al., 2006; Takahashi
and Yamanaka, 2006). Thus, understanding the mechanism and
identifying factors involved in the regulation of SOX2 expression
is a relevant topic.
We described that inhibition of PPARβ/δ decreases the level
of SOX2, but also changes the phenotype of these cells, induc-
ing differentiation. Adult NPCs culture display high percentage
of SOX2 and Nestin positive cells (∼95%). The evaluation of the
PPARβ/δ activation effect on population phenotypes is techni-
cally difficult, but it would be interesting to address if ectopic
expression of SOX2 and even PPARβ/δ activation on specific-
phenotype committed precursor (to neuron, astrocyte or oligo-
dendrocyte; SOX2−/Nestin−) can return them into an earlier
precursor stage (SOX+/Nestin+).
Interestingly, SOX2 presents a positive feedback with EGFR
in embryonic NPCs involved in self-renewal (Hu et al., 2010).
EGFR is a membrane receptor of several extracellular ligands,
including EGF, but also can be transactivated by external inputs
via interaction with other pathways, such as SHH, acting as a
nodal mediator in the control of cellular behavior (Reinchisi et al.,
2013). In vivo, EGFR is expressed in the SVZ, mainly in acti-
vated neural stem cells (B-cells) and in the transit-amplifying
C-cell population (Doetsch et al., 2002; Pastrana et al., 2009).
This population, in response to EGF, increases its proliferation
and maintains the multipotent characteristic (Doetsch et al.,
2002). In vitro, maintenance of adult mice NPCs cultures requires
EGF; deprivation of this ligand in the medium induces sponta-
neously differentiation to neurons, astrocyte and oligodendro-
cytes. Interestingly, PPARβ/δ is a mediator of the EGF-EGFR
pathway in skin, one of the organs where this transcription fac-
tors is highly expressed. In HaCat keratinocytes, EGF induces
up-regulation of PPARβ/δ expression, increased DNA binding
and promotes its transcriptional activity. Conversely, PPARβ/δ
knockdown leads to decreased EGF-mediated cell proliferation
(Liang et al., 2008b). Cells pretreated with a PPARβ/δ agonist,
show a smaller percentage of apoptosis induced by TNF-α and
an increased protective effect of EGF (Liang et al., 2008a), sug-
gesting a PPARβ/δ-dependent mechanism in EGF-stimulated cell
proliferation and survival. Furthermore, PPARβ/δ is involved in
cell proliferation of other cells types such as endothelial cells
(Piqueras et al., 2007), pre-adipocytes (Hansen et al., 2001),
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human breast, prostate, gastric and hepatocellular carcinoma
cells (Glinghammar et al., 2003; Stephen et al., 2004; Nagy et al.,
2011). Our results show that a PPARβ/δ antagonist is able to
decrease level of EGFR and proliferation of cells after 48 h of
treatment, but no increase was observed when cells were treated
with the agonist. Although at this moment we have no expla-
nation for this last result, we can not rule out that the effect
in this context requires a longer period of analysis. Additional
approaches addressing the relationship of PPARβ/δ and EGFR
signaling pathways will have to be undertaken in order to obtain
a better understanding of how and when these pathways interact
to control NPCs behavior.
Our data suggest that regulation of EGFR level and prolif-
eration of cells by PPARβ/δ antagonists can be consequences
associated with changes in the phenotype of the NPCs, as we
show that antagonists induce differentiation, even in presence
of EGF. In addition, the absence of changes in EGFR level after
activation of PPARβ/δ seem to be contradictory with the evi-
dence of the positive feedback between EGFR and SOX2 in
neural precursor cells, but this could just be due to the tim-
ing evaluated in this study. Also, it might be possible that
PPARβ/δ acts as a mediator of the EGF-EGFR pathway mod-
ulating self-renewal function through the regulation of SOX2,
however this hypothesis requires more experimental evidence to
be confirmed.
On the other hand, we also show that PPARγ regulates
EGFR level as well as proliferation of adult NPCs. Rosiglita-
zone, a PPARγ agonist, increases the level of EGFR at 12 h post-
treatment, which is maintained at least until 24 h. Overexpression
of this transcription factor is sufficient to induce an increase of
EGFR level. Concomitant with this effect, ligands of PPARγ reg-
ulate proliferation of adult NPCs, indicating that this PPAR iso-
form is involved in the control of proliferation and maintenance
of NPCs, probably acting through the transcriptional control of
EGFR. We observed that cultures deprived of EGF in order to
induce differentiation of NPCs and treated with Rosiglitazone,
present a higher number of Nestin positive cells at 48 h of treat-
ment. Even if the effect of Rosiglitazone is not sufficient to main-
tain the cells in undifferentiated phenotype after 72 h of EGF
deprivation (differentiation assays; data not shown), we observe
a slower rate of differentiation. Wada et al. reported an increase
of cell viability in embryonic NPCs treated with rosiglitazone
(PPARγ agonist) and interestingly, stated that NPCs obtained
from embryonic PPARγ-KO mice (E13.5) have decreased size
and numbers. Moreover, this group reported regulation of EGFR
by PPARγ, and suggested that regulation of proliferation by
PPARγ could be mediated by regulation of EGFR (Wada et al.,
2006). Consistent with these data, Burrows et al. showed that level
and density of EGFR are important for cell fate and prolifera-
tion of NPCs, and that cell response depends, at least partially,
on ligand concentration (Burrows et al., 1997). However, our
observations are in disagreement with results from in vitro exper-
iments published by Morales-Garcia et al. (Morales-Garcia et al.,
2011). They proposed that pioglitazone and rosiglitazone, PPARγ
agonists, induce differentiation of NPCs in vitro. One explana-
tion for these opposite findings could be the different model
systems used (rat vs. mouse), but also, and more importantly,
the concentration of the drugs used in the study. Morales-Garcia
used 30µMof rosiglitazone in a pre-treatment of 7 days, previous
to the differentiation assay (Morales-Garcia et al., 2011). Rosigli-
tazone binds to the PPARγ ligand-binding domain with a Kd of
43 nM and activated a luciferase reporter vector with an approx-
imately EC50 of 0.1 uM (Lehmann et al., 1995) and pioglitazone
and rosiglitazone at a concentration 10µM, induce activation of
PPARα, in COS-1 cells (Sakamoto et al., 2000). Moreover, Wada
et al. showed that in embryonic neurospheres, rosiglitazone has a
biphasic effect. At low concentrations, this agonist induces pro-
liferation and maintenance of a stem/precursor state, but at a
concentration 30µM or more, rosiglitazone induces apoptosis
(Wada et al., 2006). However, Morales et al., showed an inter-
esting effect in vivo, with an increase of proliferation in the SVZ
that consequently leads to increase in neurogenesis, revealing
that the size of the NSC population in the SVZ is important in
the regulation of neurogenesis. Thus, the in vivo pharmacologi-
cal activation of PPARγ, by thiazolidinedione, could be an early
event in the increase of the NPCs population with the conse-
quent increase in neurogenesis (and as such not necessary a direct
induction of differentiation). Accordingly, when Ghoochani et al.
evaluated the expression of PPARγ in the process of differentia-
tion from embryonic stem cells to neurons, they observed that
the level of PPARγ were increased in the formation of NPCs but
then decreased in terminal neuronal differentiation (Ghoochani
et al., 2012). Added to that, pharmacological treatment with lig-
ands at different times of the differentiation process revealed that
inactivation of PPARγ at early stage in mESC decreased the for-
mation of NPCs, and later of neurons and astrocytes (Ghoochani
et al., 2012).
Our results demonstrate that PPARs seem to be active endoge-
nously, at least in vitro. Thus, an interesting question is to answer
which endogenous ligands can be mediating the effect of PPARs
in neural precursor cells. PPARs are described to be nuclear tran-
scription factors and sensors of the lipid metabolism. Known
endogenous PPAR ligands in the brain include omega-3 fatty
acids, docosahexaenoic acid (DHA) and eicosapentanoic acid
(EPA). These ligands have been described to have neuropro-
tective effects (reviewed in Michael-Titus and Priestley, 2014)
and to be involved in proliferation and differentiation of NPCs
(Dyall et al., 2010; Sakayori et al., 2011). Another interesting
family of endogenous ligands of PPARs is the endocannabinoids
(Reviewed in Pistis and Melis, 2010). Activation of the endo-
cannabinoid system inNPCs by a synthetic ligand increases cellu-
lar proliferation as well as both number and size of neurospheres
(Aguado et al., 2005). CB1 receptor, a key component of this sys-
tem, was described to be required for neurospheres formation
(Aguado et al., 2005) and even more, for neurogenesis in vivo (Jin
et al., 2004). The roles described for all these ligands in neural
precursor cells, positions them as the main candidates to medi-
ate PPAR functions in NPCs, but further investigation will be
required to identify specific ligands associated to PPAR function
in NPCs.
Finally, we observed that PPARγ agonist is also able to
increase PPARβ/δ level, suggesting a possible cooperative effect of
these two isoforms of PPAR, which suggest a possible mechanism
in NPCs where PPARγ and PPARβ/δ could be mediators between
EGFR and SOX2 positive feedbacks, contributing thereby to
maintain an undifferentiated phenotype in adult SVZ-NPCs.
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Supplementary Figure 1 | pMyc-PPARβ. (A) Double anti-Myc/anti-PPARβ
immunofluorescence. Representative confocal microscopy images are shown. (B)
Myc-PPARβ expression was evaluated by western blot with anti-PPARβ and
anti-Myc antibodies. pPPARβ was used as a control of wild type protein
overexpression. pCDNA3-Myc and pCMX are empty vectors for pMyc-PPARβ and
pPPARβ, respectively. (C–E) Functional analysis of pMyc-PPARβ by luciferase
reporter assay. Cells were transfected with the vectors as indicated plus PPRE
luciferase reporter vector and pCMXβ as a control. Luciferase activity was
measured and shown in respect to control vector (pCMVβ). (C) Cells were treated
with PPARβ/d agonist (GW, 1µM) or vehicle (DMSO) for 24 h. (D) Different
concentrations of GW0742 were used to evaluate activity and to compare both
vectors. (E) Cells were pre-treated with antagonist (GSK) for 1 h and then
co-treated with PPARβ/d agonist (GW) and antagonist (GSK) for additional 24 h
(∗p < 0.05, ∗∗p = 0.01–0.001, ∗∗∗p < 0.001; One-Way ANOVA-Bonferroni test).
GW, GW0742; GSK, GSK0660; DM, DMSO.
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